A Better Life For Patients With Rare Diseases

Learn More

About

News

Our Work

Our Pipeline

ACERAGEN

Our Vision

Aceragen is a rare disease biopharmaceutical company. We take on rare, orphan diseases that typically have no approved treatments, and to develop important therapies to help patients. The needs of patients who suffer from under-served rare diseases drive our mission.

Learn More

Patient Info

The needs of patients who suffer from unserved or under-served rare diseases drive our mission at Aceragen

Learn More

Farber Disease

Farber disease is a lysosomal storage disorder that is characterized by acid ceramidase deficiency. It leads invariably to progressive disease, often with profound morbidity and premature death.

Learn More

Melioidosis

Melioidosis is a life-threatening infectious disease caused by the facultative intracellular gram-negative saprophyte B. pseudomallei, endemic throughout Southeast Asia and occurring sporadically in other regions of the world.

Learn More

Cystic Fibrosis

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and declining lung function over time. There are over 70,000 cystic fibrosis patients globally with approximately 30,000 patients in the United States.

Learn More

Latest News

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C....

  • January, 2023
  • | by Aceragen
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational...

  • November, 2022
  • | by Aceragen
View All News